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ABSTRAK 
REMUNGKINAN UNTUK MENGEVAL UASI VAKSIN MALARL-4 
DI INDONESIA 
Di Indonesia, khususnya di Irian Jaya dun daerah malaria tinggi lainnya terdapat kesempatan 
yang sangat baik untuk mengevaluasi vaksin malaria. Hal ini antara lain disebabkan tersedianya data 
epidemiologi termasuk insidens, risiko malaria yang tinggi dun merata pada berbagai kelompok umur, 
jenis kelamin dun pekerjaan, adanyo kelompok masyarakat yang sesuai untuk penelitian (transmigran 
dun angkatan bersenjata), lokasi desa yang memungkinkan randomisasi serta tersedianya fasilitas 
laboratorium di dekat daerah penelitian. 
Pemberantasan malaria dengan vaksinasi diharapkan akan menjadi fokus dari penelitian 
kesehatan menjelang akhir abad ke-20. Indonesia yang terdiri dari berbagai pulau memungkinkan 
konsolidasi pemberantasan malaria secara bertahap. Pengalaman yang diperoleh dengan 
pemberantasan malaria di suatu pulau akan sangat bermanfaat untuk menghadapi masalah yang Iebih 
berat yakni malaria di daratan luas seperti AAfrka atau daratan Asia Tenggara. 
INTRODUCTION 
Despite decades of intensive, worldwide 
effort, malaria remains one of the leading 
causes of morbidity and mortality in tropical 
countries. While vector control, antimalarial 
drugs, bednets and other measures have had a 
positive impact in limiting the disease, none has 
achieved the long term goal of eradication, and 
in some areas the situation is worsening despite 
these control measures. Nevertheless, there is a 
feeling of optimism in the malaria research 
community as we develop our newest weapon in 
the fight against this disease: vaccines. It is 
hoped that vaccines will significantly reduce 
malaria morbidity and mortality, and, in 
conjunction with other measures, lead to 
malaria eradication. 
Despite economic growth and progress in 
development, Indonesia continues to suffer from 
malaria. In the eastern provinces, including 
some developed areas such as northern 
Sulawesi, malaria remains a leading cause of 
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illness. Populations particularly heavily 
aEected include indigenous populations in Irian 
Jaya, transmigrants moving to eastern 
Indonesia, and military personnel deployed to 
eastern Indonesia. The latter two groups may 
lack immunity to malaria and thus are 
susceptible to severe disease. 
Eradicating malaria is difficult in tropical 
countries because the warm climate supports 
year round vector reproduction, resulting in 
hlgh rates of transmission. A more radical 
interruption of the malaria cycle is needed than, 
for example, was needed in Europe or North 
America, where standard control measures 
easily reduced transmission below the threshold 
required for the disease to persist. Thus 
vaccines are likely to be especially helpful 
(particularly for groups such as transmigrants 
and military personnel) in improving health 
conditions in tropical countries, where more 
intense intervention is needed. 
For this reason, it is important for 
Indonesia to participate in vaccine development. 
Vaccine trials conducted here in Indonesia will 
help us to understand their potential 
contribution to malaria control and eradication 
on Indonesian soil. This article describes the 
study sites and study populations in Indonesia 
that could participate in an evaluation of 
vaccine efficacy. 
Malaria vaccines target different stages of 
the Plasmodium falciparurn parasite according 
to the antigens from which they are formulated. 
Vaccines will thus have a differential (or stage 
specific) impact on the parasite according to 
their antigenic composition. For this reason, 
the outcome variables to be measured in a 
vaccine trial and thus the design of the trial 
depend upon the antigenic components of the 
malaria vaccine. This presentation on the 
opportunities for malaria vaccine trials in 
Indonesia is divided into sections according to 
vaccine composition, as the outcome variables 
and corresponding study design are different in 
each case. 
SPOROZOITE VACCINES 
The first vaccine tested in blinded 
controlled trials, R32ToxA from the Walter 
Reed Army Institute of Medical Research, was 
based on sequences from the P. falciparurn 
circ~lmsporozoite protein'. Its potential efficacy 
relied upon inducing an immune response that 
could affect sporozoites during the brief period 
of circulation (as little as five minutes) prior to 
binding to hepatocytes, thereby preventing 
hepatocyte invasion and further development. 
The immune response to this vaccine would 
have little effect on blood stage parasites, and 
break-through infections would be expected to 
show normal parasitemia levels and clinical 
severity. For sporozoite vaccines such as 
R32ToxA, the most important outcome variable 
to measure in a vaccine trial is the incidence of 
malaria infection following vaccination, as 
detected by newly developing parasitemia. To 
achieve this, cohorts of volunteers cleared of 
malaria (or never infected) are followed 
longitudinally with periodic blood smears to 
actively detect new parasitemias. 
Indonesia has two populations where 
protection from malaria with an effective 
vaccine would be vitally important and which 
could suppori the trial design required for a 
blinded evaluation or vaccine efficacy: 
transmigrants and military personnel. The best 
developed site for both populations, Arso 
District, is located 70 km (one and a half hours 
by car) from Jayapura. Trials involving either 
transmigrants or military personnel are possible 
at this or similar sites in eastern Indonesia. 
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Transmigrants 
Adults and children without previous 
malaria exposure move from the densely 
populated islands of Java and Bali (less than 
one case of malaria per 10,000 person years) to 
frontier areas in Irian Jaya characterized by 
frequent malaria transmission (three to four 
cases per person year). An epidemic of malaria 
usually occurs within six months of the 
establishment of a new transmigration 
community, with accompanying morbidity and 
mortality. Studies by Baird and colleagues2 
suggest that by eighteen months to two years, 
transmigrants develop a degree of immunity to 
parasitemia and to clinical symptoms associated 
with parasitemia, although this seems more 
pronounced in adults than children. 
Transmigrants thus provide a continuum of 
immunological experience with malaria, from 
naive to semi-immune. This is important 
because immune status may affect vaccine 
efficacy. It is possible to find populations in 
Arso with malaria exposure histories of zero, 
one year, two years, three years, up to more than 
ten years. 
The Arso subdistrict contains 
approximately 25,000 people, 80% of which are 
transmigrants from Java, living in 
approximately twenty villages. Transmigration 
village population size varies from 1000 to 1500 
' people in 250 to 350 houses that are arranged 
geometrically in grids. Villages are discrete 
units, with agricultural land or forest extending 
between villages. While all four species of 
malaria occur in Arso, 99% of infections are 
due to P. jblciparuni or P. vivax, which are 
generally found in a two:one ratio during 
prevalence surveys. Slide positivity rates during 
prevalence surveys vary from 5 to 50% for P. 
falciparurn and from 5 to 30% for P. vivax. 
Transmission occurs year round with a relative 
peak season extending from December through 
Febnwy. /Inopheltr.s ko!icrisa'.i. { A i l .  p~incfr;la~us 
group) is the primary vector. Malaria attack 
rates average about two P. falciparum infections 
per person per year and about one P. vivax 
infection per person per year. Table 1 contains 
several incidence measurements made during 
the past five years in Arso. 
An important aspect of malaria 
transmission by An. punctulatus complex in 
Arso is that malaria risk derives from local 
exposure near people's homes and appears 
uniformly distributed according to age, sex and 
occupation. This is because 1) the vector 
?refers open, sunlit breeding places such as 
occur on the roads and the disturbed land 
around people's homes, 2) the vector feeds 
indoors and outdoors with equal frequency 
exposing both those who are sleeping and those 
who are outdoors at night and 3) the vector 
feeds throughout the night with only slight 
increases at around midnight relative to the rest 
of the feeding period. Because these factors 
even out risk among individuals, there are no 
particular groups at greater risk of infection 
who are likely to introduce a bias and thus 
confound interpretation of vaccine trial results. 
Both P. falciparum and P. vivax are highly 
resistant to chloroquine in Arso. Resistant rates 
range from 80 to 90% for P. falciparum and 
from 70 to 80% for P. vivax as measured in 
vivo. Despite this, chloroquine remains the 
standard first line drug for treating malaria 
infections in Arso because a majority of 
individuals experience a satisfactory clinical 
response to chloroquine therapy, even if their 
infection is not eradicated. Fansidar is the 
second line drug, and quinine is used for 
clinically resistant or severe cases. There is no 
evidence for quinine resistance in Arso. 
Chloroquine, Fansidar and quinine are readily 
available in local pharmacies, while artemisinin 
derivatives, mefloquine and halofantrine are not 
licensed for use in Indonesia and are not 
a\,ailable. 
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Table 1. Summary of P.faCciparum Attack Rates Measured in Arso, Irian Jaya. 
+ other sites unpublished data (FIR IV and X, JKB; XI, DJF; military, C. Ohrt). 
* Attack rate whle on chloroquine prophylaxis (unsupervised). 
** Attack rate while on chloroquine prophylaxis (supervised). 
*** Attack rate expressed as cumulative incidence to adjust for drop-outs due to P. vivax infections. 
Other attack rates are crude (# new falciparum infections X 100 / size of cohort at start, for the 
specified interval under "follow-up). 
Years TMG = years since transmigration 
LTS = low transmission season 
HTS = high transmission season 
NA = not applicable. 
Chloroquine prophylaxis is administered 
to new transmigrants for a period of three 
months following arrival in Arso. A recent trial 
showed that as a prophylactic agent, 
chloroquine is no different from placebo in 
preventing malaria infection in Arso. As 
mentioned, however, its efficacy in preventing 
disease (as opposed to infection) probably 
provides a level of protection for new 
transmigrants. 
In order to conduct a vaccine trial, it would be 
ideal if transmigrant populations could be 
identified in Java or Bali before departure so 
that a six month series of three immunizations 
could be completed prior to arrival in Irian Jaya. 
However, this has not proved feasible. The 
most realistic vaccine trials in naive 
transmigrants would provide the first 
immunization on arrival. The cohort could be 
maintained on malaria prophylaxis during the 
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period of immunization. Following the third 
immunization with malaria vaccine, 
prophylaxis would be stopped and the cohort 
followed prospectively to measure malaria 
incidence (attack rate) in those who had 
received vaccine and those who had received 
placebo. With the use of a placebo in such trials 
(required by WHO direction), it is important 
that study participants not be subjected to 
malaria risks any greater than would normally 
occur if they weren't participating. Usually it is 
possible to reduce the risk of malaria illness or 
death relative to the normal situation, despite 
the use of a placebo, by providing excellent 
on-site diagnostic and treatment capability 
during the trial. 
With regard to the best drug for 
prophylaxis during vaccination, Fryauff and 
colleagues have shown that daily primaquine is 
an effective prophylactic agent against 
chloroquine resistant P. falciparunr and 
chloroquine resistant P. vivax in Arso @F, 
unpublished data). Unlike chloroquine, 
primaquine does not appear to suppress the 
immune response to vaccine components (DJF, 
unpublished data). In a recent study, tetanus 
toxoid was administered to transmigrants who 
had been on primaquine prophylaxis for one 
year and to a similar number of transmigrants 
who had been on placebo for one year. There 
were no significant differences in either 
serological or cellular immune responses to the 
tetanus antigen between the primaquine and 
plqcebo groups, indicating that prophylaxis with 
primaquine during vaccine administration 
should not interfere with the development of an 
inlmrlne response to vaccine antigens. 
An al~crnativc dzsign would be to provide 
vaccine to transmigrants already in residence in 
Arso and thus already esp~sed lo malaria. Prior 
to immunization the cohort would receive 
radical cure. This is the study design of the 
recent trial of SPf66 malaria vaccine in 
Tanzania3. The Ministry of Health in 
collaboration with NAMRU-2 has shown that 
the combination of quinine sulfate for four days, 
doxycycline hyclate for ten days, and 
primaquine phosphate for 14 days has 100% 
eficacy in achieving the radical cure of both the 
blood and liver stages of malaria in Arso. 
Currently, we are evaluating the combination of 
halofantrine and primaquine, which is easier to 
administer and better tolerated. Following 
radical cure, the cohort would be immunized 
and then either maintained on prophylaxis for 
six months until the third injection was 
con~pleted or given radical cure a second time, 
either to the whole cohort or to only those 
individuals becorning parasitemic during the six 
month interval.' Following the third 
immunization, the surveillance period would 
begin. 
Primaquine administration is an important 
part of radical cure. Without clearing the liver 
of hypnozoites, a large proportion of study 
subjects will develop P. vivax relapses during . 
the surveillance period. If this occurs, these 
study subjects can not be counted when 
determining vaccine eficacy. 
Military 
Military posts are present throughout the 
Arso district. Malaria naive (or remotely 
exposed) soldiers are deployed to Arso for 
periods of one year. Deployment dates are 
scheduled far in advance and a battalion could 
be fully immunized prior to arrival in Arso. 
Attack rates appear to be higher in soldiers than 
in transmigrants, making the military an ideal 
study ropulatio~l for benefitting from a malaria 
vacc~ne. In a recent field trial (C. Ohrt, 
persona! cor.ln~llnrcation). attack rates indicate 
, 
five to SIX infections per soldier per year 
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(roughly four P. falciparurn infections and two 
P. vivax infections). It is reported that in other 
locations besides Irian Jaya, such as Timor 
Timur, soldiers experience high attack rates of 
malaria. Thus battalions deployed to other sites 
besides Arso could significantly benefit from 
participation in vaccine trials. 
ASEXUAL BLOOD STAGE VACCINES 
The most widely tested P. falciparunz 
vaccine, SPf66 (developed in Colombia by Dr. 
Manuel Patarroyo and colleagues) includes 
sequences from three blood stage proteins (also 
included is a short peptide sequence derived 
from circumsporozoite protein). For blood stage 
vaccines, an important outcome variable is the 
incidence of new parasitemia, just as with 
sporozoite vaccines. This is because the blood 
stage vaccine could prevent parasitemia from 
reaching patent levels after the organism leaves 
the liver, even if the liver stages themselves are 
not affected. Additional outcome variables 
important to blood stage vaccines are the level 
of the parasitemias that occur (the vaccine could 
reduce parasitemia levels even if parasitemia is 
not prevented), and the degree of clinical 
severity associated with parasitemia (the 
immune response to the vaccine could blunt the 
pathological expression of blood stage infections 
by neutralizing malaria proteins). To measure 
these variables, cohorts are followed 
longitudinally as with sporozoite vaccines. but 
level of parasitemia and degree of clinical 
illness become important outcome variables in 
addition to incidence of parasitemia. 
If the goal of the vaccine is to prevent 
disease and not infection, active case detection 
using blood smears is not required. Rather, 
participants may be visited several times a week 
to ask about symptoms, and blood smears made 
only in symptomatic individuals. in other 
words, a purely clinical outcome variable is an 
acceptable measurement for blood stage 
vaccines designed to counter disease rather than 
infection. This is an appropriate design for 
studies involving children, where it is d1,sirable 
to minimize blood drawing. Relatively 
infrequent blood smears can be obtained to 
compare the incidence of parasitemia 
anderlying the incidence of clinical illness. 
Because naturally acquired immunity can 
limii disease expression, the participation of 
malaria-naive vs malaria-experienced study 
subjects is an important choice when designing 
blood stage vaccine trials. As malarial illness is 
more severe in naive ~ndividuals, anti-disease 
effects of blood stage vaccines might be picked 
up with greater sensitivity in study populations 
that have not previously been exposed to 
malaria. On the other hand, it is easier to 
justify the use of placebo in a malaria 
experienced study group. The use of placebo is 
generally a requirement of WHO sponsored 
vaccine trials. 
Opportunities for studying blood stage 
vaccines in Indonesia are excellent. Both 
transmigrants and soldiers could be considered 
for prospective, longitudinal studies in which 
vaccine or placebo are blindly and randomly 
provided to the study cohort. As mentioned, a 
range of malaria experience is available in the 
transmigrant population. Active case detection 
with blood smears, symptom questionnaires or 
both can be used to detect outcome variables. In 
the case of the military, vaccination can be 
completed prior to exposure to malaria. 
Vaccine trials should be considered for 
people with lifetime exposure to malaria, as is 
often the case in villages of indigenous peoples 
in Irian Jaya. It is critical that vaccines be 
developed that will benefit those living 
permanentlv in malaria areas. Because of their 
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potential efficacy in reducing clinical disease, 
blood stage vaccines should be targeted toward 
these populations. 
Clinical measures are particularly 
important for blood stage vaccine trials. Partly 
to address this need, the Ministry of Health and 
NAMRU-2 maintain clinical and research 
laboratories in Jayapura that by the end of 1995 
will be certifiable as Good Laboratory Practices 
(GLP) facilities. In addition, the presence of 
laminar flow hoods, CO, incubators, high speed 
centrifuges, liquid nitrogen and other laboratory 
equipment in Jayapura allows sophisticated 
immunological and other assays to be performed 
on site in conjunction with vaccine trials. There 
is 24 hour field telephone, field radio, and 
regular telephone and fax communication 
between Jayapura and Jakarta. The daily flights 
between the two cities facilitates transport of 
specimens, supplies and equipment. 
GAMETOCYTE STAGE VACCINES 
Transmission blocking vaccines based on 
gametocyte, gamete or ookinete proteins should 
not affect parasitemia or clinical illness in 
vaccine recipients, because gametocytes 
themselves do not cause pathology in the human 
host. Useful outcome variables include oocyst 
or sporozoite counts in mosquitoes fed directly 
or through membranes on the blood of 
parasitemic vaccinees. Alternatively, if entire 
villages (or defined areas of transmission) are 
rbndomized to vaccine or placebo, attack rates 
in those villages could be used to measure 
reductions in transmission associated with a 
gametoe-.te vaccine. 
Appropriate stb +y subjects for evaluating 
transmission blocklng vaccines are 
semi-immune individuals living in malaria 
endemic areas. These individuals especially 
adults, have naturally acquired immunity to 
clinical disease when parasitemic. Thus the 
administration of a vaccine that was not directly 
beneficial in preventing malarial illness in study 
participants would be acceptable. 
The unique organization of Arso, with 
twenty transmigrant villages placed in 
semi-isolated pockets of cleared land cut from 
the jungle, offers the possibility of a large study 
in which placebo and gametocyte (or 
transmission blocking) vaccine are randomized 
between villages. Simple outcome variables 
such as point prevalence positivity, or more 
complex measures such as malaria incidence or 
entomologic inoculation rate, could be used to 
monitor the effect of vaccination on a particular 
village. It could be predicted that an effective 
transmission blocking vaccine would eliminate 
malaria from vaccinated villages. Thus by 
using this study design, ultimately very large 
benefits can be derived for vaccine recipients. 
An alternative design is to use the modest 
prevalence of P. vivax as an internal control. In 
this way, the ratio of P. falciparum to P. vivax 
would be expected to decrease in villages 
receiving a P. falciparum transmission blocking 
vaccine. Either of these designs could be 
implemented in Arso, in transmigrant and 
indigenous populations. 
MULTIPLE STAGE VACCINES 
Newer vaccines under development, such 
as NYVAC7, include antigens from sporozoite, 
liver, asexual and sexual blood stages. It is 
difficult to measure the overall efficacy of such 
vaccines; if efficacy is demonstrated, it is likely 
to be unclear which antigens are responsible. 
Probably the best study design is to use a cleared 
cohort or naive cohort design as with sporozoite 
or b l c d  stage vaccines. If parasitemia is 
preveiltd, however, the potential contribution 
of the trar!srnission blocking components cannot 
be evaluated. 
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SAMPLE SIZE CALCULATIONS 
Table 2 presents sample size calculations 
for a vaccine with expected efficacy of SO%, a 
p-value (a)  of .05, and power (1-P) of 0.8. It 
can be seen that the attack rates measured in 
Arso are sufficient for a vaccine trial with a 
range of 50 to 100 individuals in each arm of 
the study, using six months of surveillance (the 
period of follow-up after the last vaccine dose), 
CONCLUSIONS 
Indonesia provides excellent opportunities 
for malaria vaccine evaluation. Key features: 
1) Potential health benefits for vaccine 
recipients. 
2) Well characterized study sites in Ilian Jaya. 
Extensive cpidemiological data av; ilable, 
including multiple incidence measurements. 
3) Malaria incidence sufficient for vaccine 
trials involving just a few hundred people. 
4) Malaria risk uniform among age, sex and 
occupation groups. 
5) Cooperative study populations (both 
transmigrants and military) with low 
drop-out rates. 
Table 2. Sample Size as a Function of Attack Rate 
(Assuming efficacy SO%, a = .05, power (1-P) = .8 or .95) 
* the incidence (attack rate) is measured as the number of new P. falciparum infections experienced 
by the placebo group during the period of surveillance. 
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6) Range of previous malaria exposure from 
none to ten years. 
7) Ability to vaccinate naive individuals in 
malaria free area prior to deployment to 
study site (military). 
8) Geographic layout permitting randomi- 
zation of whole villages to vaccine or 
placebo to evalcste the efficacy of 
transmission blocking vaccine. 
9) Proximity to field site of both GLP certified 
clinical laboratories and research facilities. 
If successful, the eradication of malaria 
through the use of vaccines will be one of the 
premiere health achievements on this century. 
Indonekia has the potential to play a pivotal role 
in this enterprise. It is likely that once an 
effective vaccine is developed, sponsoring 
institutions such as the World Health 
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